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ABSTRACT
OBJECTIVE
To investigate the incidence of new onset type 
2 diabetes mellitus in men receiving steroid 
5α-reductase inhibitors (dutasteride or finasteride) for 
long term treatment of benign prostatic hyperplasia.
DESIGN
Population based cohort study.
SETTING
UK Clinical Practice Research Datalink (CPRD; 
2003-14) and Taiwanese National Health Insurance 
Research Database (NHIRD; 2002-12).
PARTICIPANTS
Men in the CPRD who received dutasteride (n=8231), 
finasteride (n=30 774), or tamsulosin (n=16 270) 
were evaluated. Propensity score matching (2:1; 
dutasteride to finasteride or tamsulosin) produced 
cohorts of 2090, 3445, and 4018, respectively. In the 
NHIRD, initial numbers were 1251 (dutasteride), 4194 
(finasteride), and 86 263 (tamsulosin), reducing to 
1251, 2445, and 2502, respectively, after propensity 
score matching.
MAIN OUTCOMES MEASURE
Incident type 2 diabetes using a Cox proportional 
hazard model.
RESULTS
In the CPRD, 2081 new onset type 2 diabetes 
events (368 dutasteride, 1207 finasteride, and 506 
tamsulosin) were recorded during a mean follow-
up time of 5.2 years (SD 3.1 years). The event rate 
per 10 000 person years was 76.2 (95% confidence 
interval 68.4 to 84.0) for dutasteride, 76.6 (72.3 
to 80.9) for finasteride, and 60.3 (55.1 to 65.5) for 
tamsulosin. There was a modest increased risk of type 
2 diabetes for dutasteride (adjusted hazard ratio 1.32, 
95% confidence interval 1.08 to 1.61) and finasteride 
(1.26, 1.10 to 1.45) compared with tamsulosin. 
Results for the NHIRD were consistent with the 
findings for the CPRD (adjusted hazard ratio 1.34, 
95% confidence interval 1.17 to 1.54 for dutasteride, 
and 1.49, 1.38 to 1.61 for finasteride compared with 
tamsulosin). Propensity score matched analyses 
showed similar results.
CONCLUSIONS
The risk of developing new onset type 2 diabetes 
appears to be higher in men with benign prostatic 
hyperplasia exposed to 5α-reductase inhibitors 
than in men receiving tamsulosin, but did not differ 
between men receiving dutasteride and those 
receiving finasteride. Additional monitoring might be 
required for men starting these drugs, particularly in 
those with other risk factors for type 2 diabetes.
Introduction
Previous studies suggest that commonly used drugs, 
such as antihypertensives,1 statins,2 3 antipsychotics,4 
antiretrovirals,5 immunosuppressants,6 and 
corticosteroids,7 increase the risk of type 2 diabetes 
mellitus. Recent findings8 9 show that steroid 
5α-reductase inhibitors might also be implicated. 
5α-reductase inhibitors are prescribed to treat benign 
prostatic hyperplasia (BPH), a disease affecting 
approximately 50% of older men. These drugs are 
usually prescribed if α blockers have been ineffective 
or the prostate gland is substantially enlarged.10 
5α-reductase inhibitors prevent conversion of 
testosterone to the more active 5α-dihydrotestosterone 
and reduce androgen dependent prostate growth.11 
Two 5α-reductase inhibitors are marketed: finasteride, 
first in class, which selectively inhibits 5α-reductase 
2; and dutasteride, which inhibits 5α-reductase 2 and 
5α-reductase 1. Although 5α-reductase 2 is highly 
expressed in prostate and skin, 5α-reductase 1 is also 
active in metabolic tissues (liver, adipose, and skeletal 
muscle).8
A recent short term experimental medicine study 
showed that dutasteride induces insulin resistance, 
a major risk factor for type 2 diabetes; however, 
neither finasteride nor the α blocker tamsulosin had 
this effect.8 Moreover, dutasteride administered for 
three weeks promotes hepatic steatosis, although 
this result was not found for finasteride.9 Traish and 
colleagues reported increased blood glucose and 
glycated haemoglobin A1c after approximately three 
years of dutasteride treatment, but did not assess the 
effect of finasteride.12 These findings are consistent 
with increased susceptibility to diet induced obesity, 
impaired glucose tolerance, and fatty liver reported in 
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Srd5a1-/- mice; similar changes were found in obese 
rats receiving dual 5α-reductase inhibitors.13 14 Men 
requiring drug treatment for BPH are older and more 
susceptible to type 2 diabetes, so treatments that 
exacerbate this risk should be avoided. A previous 
study that reported a lower risk of type 2 diabetes in 
men receiving 5α-reductase inhibitors did not account 
for baseline metabolic differences.15
We investigated whether treatment with dutasteride 
or finasteride increases the risk of type 2 diabetes 
compared with tamsulosin alone in two population 
based cohorts. We also compared the risk of developing 
type 2 diabetes after dutasteride treatment and 
finasteride treatment.
Methods
Discovery cohort
We performed a population based cohort study 
using data from the UK Clinical Practice Research 
Datalink (CPRD). This database contains anonymised 
longitudinal medical records from more than 500 
primary care practices with 4.4 million active patients. 
Data have been collected since 1987 and cover 
approximately 7% of the UK population; these data 
can be generalised to the whole UK population.16
Our study population included men aged at least 
40 with a recorded diagnosis of BPH in their general 
practice notes, or prescribed dutasteride, finasteride, 
or tamsulosin. These patients were registered in 
primary care between 2003 and 2014 (Read codes, 
supplementary table S1A). Patients were followed up 
until the end of December 2014 and were censored 
if they experienced an outcome event, died, left their 
general practice during the study period, or switched 
drugs. We excluded patients if they had received 
prescriptions for finasteride or tamsulosin before 2003 
or had a history of cancer, diabetes, or oral glucose 
lowering or insulin treatment before the index date 
(date of first prescription of dutasteride, finasteride, or 
tamsulosin).
Our study period was 11 calendar years (2003-14) 
and we included three cohorts that were identified and 
followed up in a similar way. The first cohort comprised 
patients who received at least two prescriptions of 
dutasteride. These patients entered the study on the 
date of the first prescription for dutasteride (index date) 
and were included if they remained in the database for 
at least 90 days. Patients switching from dutasteride 
to finasteride or α blockers were censored at that time. 
We created a separate group of patients concurrently 
prescribed dutasteride and tamsulosin, but these 
patients were also included in a “total” cohort along 
with those prescribed dutasteride alone. A second 
cohort comprised patients who received at least two 
prescriptions of finasteride either alone or as a “total” 
cohort, which included those taking finasteride in 
combination with tamsulosin. These patients entered 
the study on the date of the first prescription for 
finasteride (index date) and were included if they 
remained in the database for at least 90 days. A third 
cohort comprised patients who received at least two 
prescriptions of tamsulosin alone. Tamsulosin was 
selected as the representative α blocker because it is 
the most common α blocker prescribed for BPH, which 
is its sole indication. These patients entered the study 
on the date of the first prescription for tamsulosin 
(index date) and were included if they remained in the 
database for at least 90 days. We excluded patients 
prescribed tamsulosin without a recorded diagnosis 
code for BPH (international classification of diseases, 
ninth revision (ICD-9) code 600).
Primary outcome and covariates
The primary outcome was the incidence of new onset 
type 2 diabetes during the follow-up period (Read 
codes, supplementary table S1B), or prescription of oral 
glucose lowering drugs or insulin. We compared the 
incidence of new onset type 2 diabetes in the dutasteride 
and finasteride cohorts versus the tamsulosin cohort, 
and the incidence in the dutasteride cohort versus the 
finasteride cohort. Covariates included age, smoking 
status, alcohol consumption, body mass index and 
physical activity at index date, and duration of BPH; 
history of hypertension, dyslipidaemia, and chronic 
obstructive pulmonary disease; use of β blockers, 
diuretics, angiotensin converting enzyme inhibitors, 
angiotensin receptor blockers, statins, and oral 
corticosteroids in the previous three years; and health 
status assessed by the number of outpatient visits three 
months before and three months after the index date. 
We defined the duration of BPH from the date of the 
first record of BPH to the index date. For patients who 
started drug treatment without a previously recorded 
diagnosis of BPH, the duration was zero.
Analysis after propensity matching
We calculated a propensity score for each patient to 
minimise confounding by indication, when patients 
with other risk factors for type 2 diabetes might be 
more likely to receive dutasteride. We used logistic 
regression to obtain the propensity score, and the 
covariables were the confounding variables at baseline 
(age, smoking status, alcohol consumption, body 
mass index, physical activity, and duration of BPH 
from first diagnosis; history of chronic obstructive 
pulmonary disease, hypertension, and dyslipidaemia; 
health status assessed by number of outpatient visits 
three months before and three months after the index 
date; use of diuretics, angiotensin converting enzyme 
inhibitors, angiotensin receptor blockers, β blockers, 
statins, and oral corticosteroids in previous three 
years). Comparator cohorts matched by propensity 
score (within ±0.05, comprising up to two matched 
controls for each dutasteride exposed patient) were 
created using patients prescribed finasteride or 
tamsulosin from the same practice.
Replication cohort
The study was replicated using the Taiwanese National 
Health Insurance Research Database (NHIRD), 
which is a validated17 database with more than 99% 
of the population registered. The NHIRD includes 
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demographic data, information for healthcare 
professionals and medical facilities, health service 
records and expenditure claims from inpatient and 
ambulatory care, and dispensing data. Further 
datasets include patients with cancer, diabetes, dental 
problems, catastrophic illness, and psychiatric disease.
The study period was from 2002 to 2012. The 
computer software randomly drew three million 
patients from the total Taiwanese population of 
23 million. We used the same criteria for cohorts, 
participants, and outcome as described for the CPRD 
database. Only a urologist prescribed finasteride 
and dutasteride, therefore records on their use were 
considered specific for BPH. We excluded patients 
prescribed tamsulosin without a recorded diagnosis 
code for BPH (ICD-9 code 600).
Outcome and covariates
We defined the outcome of new onset type 2 diabetes 
by the first record of type 2 diabetes (ICD-9 codes 
250.x0 or 250.x2) or use of at least one oral drug for 
diabetes. We censored patients in the same way as for 
the CPRD. Covariates included age and duration of 
BPH from first diagnosis; history of chronic obstructive 
pulmonary disease, hypertension, or dyslipidaemia; 
health status assessed by number of outpatient visits 
three months before and three months after the index 
date; and previous one year use (standard assessment 
of previous drug use in Taiwanese database18) of 
diuretics, statins, angiotensin converting enzyme 
inhibitors, angiotensin receptor blockers, and oral 
corticosteroids. We performed propensity matching in 
the same way as for the CPRD database, but without 
data on body mass index, smoking status, alcohol 
consumption, and physical activity.
Statistical analysis
We summarised data as mean (standard deviation) or 
median (interquartile range) for continuous variables, 
and number (percentage) for categorical variables. 
Data distributions and Cox model assumptions were 
checked before analysis by using proportionality tests 
and log-log plots. We carried out χ2 tests, one way 
analysis of variance, and Kruskal-Wallis tests for the 
baseline characteristics. Person year time for each 
patient was calculated as the time from the index date to 
the end of follow-up. We used Cox proportional hazard 
models before and after propensity matching. In the 
UK cohort, missing data for body mass index, smoking 
status, alcohol consumption, and physical activity 
were categorised into a further group and adjusted in 
the final model to include all patients. We performed 
cumulative incidence plots and log rank tests to 
compare outcomes among the cohorts. Analyses were 
carried out using SAS software, version 9.4 (Cary, NC).
Patient and public involvement
This research was performed without patient 
involvement. We thank the patients for allowing 
their records to be retained in the databases. We have 
included patients in our dissemination strategy.
Results
Discovery cohort: CPRD
A total of 69 794 patients received at least two 
prescriptions of dutasteride, finasteride, or tamsulosin 
(fig 1). After we applied exclusions, 55 275 participants 
remained; 39 005 patients using 5α-reductase 
inhibitors were included (8231 dutasteride and 30 774 
finasteride) and 16 270 receiving tamsulosin. At 
baseline, patients receiving dutasteride or finasteride 
were older, had more comorbidities, except for 
dyslipidaemia, and used more oral corticosteroids and 
cardiovascular drugs than those receiving tamsulosin 
(table 1). There were fewer differences in baseline 
characteristics between the dutasteride and finasteride 
groups, with no differences in body mass index. 
When we included patients receiving dutasteride 
combined with tamsulosin or finasteride combined 
with tamsulosin the numbers increased by 599 and 
2622, respectively, but baseline characteristics did not 
change substantively (supplementary table S2).
Excluded
Pre-diabetes
<90 days of follow-up
Concurrent use of dutasteride and finasteride
203
10 935
160
CPRD database - Patients with at least two prescriptions of dutasteride, finasteride, or tamsulosin, 2003-14
69 794
Patients included
58 496
Patients included
55 275
11 298
Excluded
Dutasteride and tamsulosin
Finasteride and tamsulosin
599
2622
Dutasteride alone8231 Finasteride alone30 774 Tamsulosin alone16 270
3221
Fig 1 | Flow chart showing UK Clinical Practice Research Datalink (CPRD) study cohorts
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Analysis of main CPRD cohort
We recorded 2081 new onset type 2 diabetes events 
(368, 1207, and 506 for the dutasteride, finasteride, 
and tamsulosin groups, respectively) during a 
mean follow-up of 5.2 (SD 3.1) years (5.9 (3.1), 
5.1 (3.2), and 5.2 (3.1) for dutasteride, finasteride, 
and tamsulosin, respectively). Cohorts receiving 
dutasteride combined with tamsulosin or finasteride 
combined with tamsulosin added a further 27 and 82 
events, respectively. Therefore, there were 395 and 
1289 events in the “total” cohorts for dutasteride and 
finasteride, respectively.
The event rate was 76.2 per 10 000 person years 
(95% confidence interval 68.4 to 84.0) for dutasteride 
and 76.6 (72.3 to 80.9) for finasteride compared with 
60.3 (55.1 to 65.5) for tamsulosin. The cumulative 
incidence of developing type 2 diabetes (P<0.01) 
was higher in the dutasteride and finasteride cohorts 
compared with tamsulosin cohort (fig 2). Similar event 
rates were observed in the “total” cohorts: 76.6 (69.0 
to 84.1) for total dutasteride and 76.1 (71.9 to 80.2) for 
total finasteride. The risk of developing type 2 diabetes 
was again higher for patients receiving dutasteride or 
finasteride compared with tamsulosin (table 2). The 
increase in risk of type 2 diabetes did not differ among 
patients receiving dutasteride or finasteride alone or 
when we included patients receiving these drugs in 
combination with tamsulosin (table 2; fig 2).
Propensity score matched analysis
We included 9553 patients (2090 dutasteride, 3445 
finasteride, and 4018 tamsulosin) in the propensity 
score matching, and most baseline characteristics 
(specifically body mass index) did not differ (table 1). 
Duration of BPH was longer for the tamsulosin group 
than for the dutasteride and finasteride groups.
During a mean follow-up time of 5.7 (SD 3.2) years 
(6.5 (3.1), 5.9 (5.8), and 5.1 (4.7) for dutasteride, 
finasteride, and tamsulosin, respectively), 105, 
127, and 144 new onset type 2 diabetes events were 
recorded. The event rate per 10 000 person years 
was 77.2 (95% confidence interval 62.5 to 91.9) for 
dutasteride, 71.3 (59.7 to 82.9) for finasteride, and 
62.0 (51.2 to 72.7) for tamsulosin. The risk of type 2 
diabetes was greater in patients receiving dutasteride 
than in those receiving tamsulosin (increased 
Table 1 | Baseline characteristics for UK Clinical Practice Research Datalink cohorts receiving single drugs before and after propensity matching. Values 
are means (standard deviations) unless stated otherwise
Characteristics
Before propensity score matching After propensity score matching
Dutasteride 
(n=8231)
Finasteride 
(n=30 774)
Tamsulosin 
(n=16 270) P value
Dutasteride 
(n=2090)
Finasteride 
(n=3445)
Tamsulosin 
(n=4018) P value
Age (years) 71.9 (9.8) 72.2 (10.9) 69.1 (10.3) <0.01 71.3 (9.2) 72.1 (9.1) 71.2 (9.3) <0.01
Body mass index category*:            
 <18.5 46 (0.7) 183 (0.7) 91 (0.6) 0.01 13 (0.7) 17 (0.6) 29 (0.8) 0.48
 18.5-25 2443 (34.9) 9028 (34.9) 4794 (33.6) 644 (35.3) 1022 (34.6) 1231 (35.0)
 25-30 3282 (46.9) 11 913 (46.1) 6846 (48.1) 876 (48.1) 1423 (48.1) 1680 (47.7)
 >30 1229 (17.5) 4944 (18.3) 2518 (17.7) 290 (15.9) 496 (16.8) 581 (16.5)
Smoker*:            
 Yes 849 (10.7) 3292 (11.3) 1859 (11.8) <0.01 221 (10.9) 337 (10.3) 461 (11.9) 0.08
 No 3772 (47.6) 13 356 (45.9) 7485 (47.4) 976 (48.3) 1515 (46.1) 1810 (46.5)
 Former 3311 (41.7) 12 447 (42.8) 6458 (40.9) 826 (40.8) 1431 (43.6) 1618 (41.6)
Physical activity*:            
 Inactive 378 (9.8) 1335 (9.8) 699 (9.6) <0.01 87 (8.6) 122 (7.7) 191 (9.6) 0.04
 Gentle 1418 (36.8) 5321 (39.0) 2636 (34.1) 358 (35.4) 628 (39.5) 709 (35.6)
 Moderate 1861 (48.2) 6333 (46.4) 3917 (50.7) 508 (50.2) 764 (48.0) 965 (48.4)
 Vigorous 201 (5.2) 650 (4.8) 473 (6.1) 59 (5.8) 77 (4.8) 129 (65)
Alcohol consumption*:       <0.01      
 Yes 5915 (82.2) 21 879 (82.5) 12 233 (84.4) 1563 (84.8) 2520 (84.0) 3061 (84.8) 0.94
 No 1061 (14.7) 3831 (14.4) 1850 (12.8) 232 (12.6) 395 (13.2) 454 (1267)
 Former 220 (3.1) 820 (3.1) 416 (2.9) 49 (2.7) 84 (2.8) 96 (2.7)
Median (interquartile range) duration of BPH (days)* 14 (0-1476) 13 (0-1384) 56 (27-892) <0.01 16 (0-1521) 17 (0-1523) 56 (26-1110) <0.01
Disease history (No (%)):                
 COPD 633 (7.7) 2571 (8.4) 1169 (7.2) <0.01 159 (7.6) 271 (7.9) 332 (8.3) 0.63
 Dyslipidaemia 1235 (15.0) 4294 (14.0) 2711 (16.7) <0.01 342 (16.4) 590 (17.1) 657 (16.4) 0.62
 Hypertension 2820 (34.3) 1114 (36.1) 5241 (32.2) <0.01 717 (34.3) 1217 (35.3) 1457 (36.3) 0.30
Other drug use (No (%))†:
 β blocker 2179 (26.5) 7662 (24.9) 3471 (21.3) <0.01 538 (25.7) 834 (24.2) 936 (23.3) 0.11
 Statin 3277 (39.8) 11 704 (38.0) 5871 (36.1) <0.01 768 (36.7) 1267 (36.8) 1551 (38.6) 0.18
 ACE inhibitor 2246 (27.3) 8644 (28.1) 3844 (23.6) <0.01 524 (25.1) 913 (26.5) 1063 (26.5) 0.43
 ARB 829 (10.1) 2848 (9.3) 1359 (8.4) <0.01 183 (8.8) 321 (9.3) 397 (9.9) 0.35
 Diuretic 2445 (29.7) 9315 (30.3) 3669 (22.6) <0.01 584 (27.9) 956 (27.8) 1044 (26.0) 0.13
 Oral corticosteroid 886 (10.7) 3095(10.1) 1497 (9.2) <0.01 222 (10.6) 319 (9.3) 420 (10.5) 0.15
No of GP contacts‡ 10.5 (2.2) 10.2 (2.3) 10.0 (2.4) <0.01 10.4 (2.3) 10.1 (2.4) 10.2 (2.3) <0.01
ACE=angiotensin converting enzyme; ARB=angiotensin receptor blocker; BMI=body mass index; BPH=benign prostatic hyperplasia; COPD=chronic obstructive pulmonary disease; GP=general 
practitioner.
*Excluding missing data.
†In previous three years.
‡Three months before or three months after index date.
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cumulative incidence; fig 2), with a point estimate 
hazard ratio of 1.34 (95% confidence interval 1.02 to 
1.75). After propensity score matching, the rate of type 
2 diabetes in the finasteride cohort no longer differed 
from the rate for tamsulosin (1.22; 0.95 to 1.57; table 
2). However, there was an increased risk of type 2 
diabetes for finasteride in the total cohorts. Again, the 
risk did not differ between dutasteride and finasteride 
when prescribed alone (1.08; 0.83 to 1.40) or when we 
included patients receiving these drugs in combination 
with tamsulosin (1.04; 0.82 to 1.31).
Replication cohort: NHIRD
Figure 3 shows the cohort selection for the NHIRD, and 
table 3 (prescribed single drugs) and supplementary 
table S3 (total cohorts receiving single drugs or 
combination treatment with tamsulosin) present 
the baseline characteristics. Taiwanese patients 
were younger than UK patients and took fewer 
drugs for cardiovascular indications, but more oral 
corticosteroids. Similarly to the UK patients, Taiwanese 
patients receiving tamsulosin were slightly younger 
than those receiving dutasteride or finasteride. More 
patients had dyslipidaemia in the dutasteride group.
Analysis of main Taiwanese cohort
We recorded 1028 new onset type 2 diabetes events 
(21, 68, and 939 for the dutasteride, finasteride, and 
tamsulosin, respectively) during a mean follow-up 
time of 3.1 (SD 4.5) years (2.2 (3.2), 3.4 (4.7), and 2.9 
(4.5) for dutasteride, finasteride, and tamsulosin). The 
event rate per 10 000 person years was 152.8 (95% 
confidence interval 144.5 to 161.5) for dutasteride and 
109.1 (105.9 to 112.5) for finasteride compared with 
74.7 (74.2 to 75.2) for tamsulosin. The event rates for 
the total cohorts were similar (155.2, 142.1 to 169.1 
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Fig 2 | Cumulative incidence of type 2 diabetes in Clinical Practice Research Datalink cohort over study period: main 
cohort (adjusted), and adjusted for propensity score
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for dutasteride combined with tamsulosin; 111.3, 97.1 
to 127.7 for finasteride combined with tamsulosin).
The risk of developing type 2 diabetes (table 2) was 
higher for patients receiving dutasteride or finasteride 
compared with tamsulosin (adjusted hazard ratio 1.34, 
95% confidence interval 1.17 to 1.54; and 1.49, 1.38 
to 1.61, respectively), but the risk for dutasteride and 
finasteride did not differ (0.90, 0.77 to 1.06). Figure 
4 shows the increased cumulative incidence of type 2 
diabetes. Results were similar in the total cohorts when 
we included patients receiving combination treatment 
(table 2).
Propensity score matched analysis
We included 6198 patients (1251 dutasteride, 2445 
finasteride, and 2502 tamsulosin) in the propensity 
score matching. Baseline characteristics were similar 
among cohorts (table 3).
The mean follow-up times were 2.9 (SD 3.4) years 
(2.2 (3.2), 3.2 (3.5), and 2.9 (3.3) for dutasteride, 
finasteride, and tamsulosin, respectively). The 
associated event rates per 10 000 person years for 
type 2 diabetes were 152.8 (95% confidence interval 
144.5 to 161.5), 111.4 (107.1 to 115.8), and 79.7 
(76.6 to 82.9), with 21, 35, and 25 new onset events 
recorded. The risk of type 2 diabetes in patients 
receiving dutasteride and finasteride was higher than 
in those receiving tamsulosin: hazard ratio 1.18 (95% 
confidence interval 1.00 to 1.40) and 1.61 (1.46 to 
1.80), respectively; however, the risk did not differ 
between dutasteride and finasteride (0.94, 0.80 to 
1.11; table 2). Figure 4 shows the increased cumulative 
incidence of type 2 diabetes. These findings were 
corroborated by the results for the total cohorts, 
which also included patients receiving combination 
treatments (table 2).
Discussion
Previous short term studies suggest that dutasteride 
but not finasteride might increase the risk of type 2 
diabetes by impairing insulin sensitivity and increasing 
steatosis.8 9 13 14 19 Our pharmacoepidemiological 
Table 2 | Hazard ratios of incident type 2 diabetes mellitus in the UK CPRD and Taiwanese NHIRD cohorts
Cohort
Primary analysis Matched by propensity score
Unadjusted hazard ratio (95% CI) Adjusted hazard ratio* (95% CI) Adjusted hazard ratio (95% CI)
CPRD:
 Finasteride alone v tamsulosin alone 1.28 (1.15 to 1.42) 1.26 (1.10 to 1.45) 1.22 (0.95 to 1.57)
 Dutasteride alone v tamsulosin alone 1.29 (1.13 to 1.48) 1.32 (1.08 to 1.61) 1.34 (1.02 to 1.75)
 Dutasteride alone v finasteride alone 1.00 (0.89 to 1.13) 1.07 (0.87 to 1.31) 1.08 (0.83 to 1.40)
 Total finasteride† v tamsulosin alone 1.27 (1.14 to 1.40) 1.22 (1.07 to 1.39) 1.32 (1.06 to 1.64)
 Total dutasteride† v tamsulosin alone 1.29 (1.13 to 1.48) 1.32 (1.09 to 1.58) 1.34 (1.05 to 1.71)
 Total dutasteride† v total finasteride† 1.02 (0.91 to 1.14) 1.08 (0.90 to 1.31) 1.04 (0.82 to 1.31)
NHIRD:      
 Finasteride alone v tamsulosin alone 1.47 (1.36 to 1.59) 1.49 (1.38 to 1.61) 1.61 (1.46 to 1.80)
 Dutasteride alone v tamsulosin alone 1.55 (1.35 to 1.78) 1.34 (1.17 to 1.54) 1.18 (1.00 to 1.40)
 Dutasteride alone v finasteride alone 1.06 (0.90 to 1.24) 0.90 (0.77 to 1.06) 0.94 (0.80 to 1.11)
 Total finasteride† v tamsulosin alone 1.49 (1.39 to 1.60) 1.50 (1.39 to 1.62) 1.48 (1.34 to 1.63)
 Total dutasteride† v tamsulosin alone 1.32 (1.15 to 1.51) 1.34 (1.17 to 1.53) 1.18 (1.01 to 1.40)
 Total dutasteride† v total finasteride† 1.05 (0.90 to 1.21) 0.89 (0.77 to 1.03) 0.82 (0.67 to 0.99)
CPRD=Clinical Practice Research Datalink; NHIRD=National Health Insurance Research Database.
*For CPRD, adjusted for age, duration of condition, body mass index, smoking status, alcohol consumption, physical activity, previous medical conditions (chronic obstructive pulmonary disease, 
dyslipidaemia, and hypertension), number of general practitioner contacts, and use of corticosteroids and cardiovascular drugs; for NHIRD, adjusted for age, duration of condition, previous 
medical conditions (chronic obstructive pulmonary disease, dyslipidaemia, and hypertension), number of general practitioner contacts, and use of corticosteroids and cardiovascular drugs.
†Cohorts of patients receiving 5α-reductase inhibitor alone or in combination with tamsulosin.
Excluded
Pre-diabetes
<90 days of follow-up
Concurrent use of dutasteride and finasteride
7757
13 064
957
NHIRD - Patients with at least two prescriptions of dutasteride, finasteride, or tamsulosin, 2002-12
Patients included
92 418
Patients included
91 708
21 778
Excluded
Dutasteride and tamsulosin
Finasteride and tamsulosin
204
506
Dutasteride alone1251 Finasteride alone4194 Tamsulosin alone86 263
710
114 196
Fig 3 | Flow chart showing Taiwanese National Health Insurance Research Database (NHIRD) study cohorts
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analyses show that the incidence of type 2 diabetes was 
increased in patients with BPH receiving dutasteride 
compared with tamsulosin, but an increased risk was 
also seen in patients receiving finasteride. In the UK, 
for every 10 000 person years of treatment, type 2 
diabetes occurs in 76 patients treated with dutasteride 
or finasteride, but only in 60 patients treated with 
tamsulosin. These data are comparable to the increased 
incidence of type 2 diabetes with statin use.2 The risk 
we identified is modest, but consistent between the 
two study populations. We performed a sensitivity 
analysis by propensity score matching for differences 
in baseline variables, including body mass index and 
statin use, and the increased risk of developing type 
2 diabetes remained. Our findings were replicated in 
the Taiwanese cohort: we recorded 78 and 35 extra 
events for every 10 000 person years of treatment for 
dutasteride and finasteride, respectively, compared 
with tamsulosin, against an overall higher incidence 
of type 2 diabetes in the Taiwanese population. We 
observed this increased risk whether dutasteride or 
finasteride was prescribed alone or combined with 
tamsulosin.
Strengths and weaknesses of this study
A major strength of this study was the cohort design. 
We used two large healthcare databases with different 
ethnic populations and made adjustments for known 
confounders. Our findings reflect usual healthcare 
practice in the UK and can be generalised to other 
populations. Nonetheless, differences in practice 
were apparent between the two countries. The 
healthcare system in Taiwan does not have primary 
and secondary care divisions and has less emphasis 
on health screening and preventive treatments, such 
as statins. Overall type 2 diabetes incident rates 
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Fig 4 | Cumulative incidence of type 2 diabetes mellitus in Taiwanese National Health Insurance Research Database 
cohort over study period: main cohort (adjusted), and adjusted for propensity score
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were higher in Taiwan than in the UK, with younger 
patients affected. This finding is consistent with 
Asian populations having higher incident rates of 
type 2 diabetes than European populations.20-22 The 
Taiwanese database does not contain data for body 
mass index, smoking status, and alcohol consumption, 
and we could not control for these potential biases. 
Body mass index is a potential confounding risk factor 
for type 2 diabetes, but the comparable risk for both 
5α-reductase inhibitors persisted in the CPRD cohort 
after adjustment and after effective matching by 
propensity score. Moreover, we conducted a further 
survival analysis with a time dependent variable 
of body mass index, and the results remain similar 
(supplementary table S4). In the NHIRD there is also a 
lack of detailed information on socioeconomic factors, 
lifestyle behaviours, imaging, and biochemical data. 
The follow-up period was shorter in Taiwan and 
could reflect differences in prescribing practices or 
the healthcare setting. We used the well established 
method of grouping all missing data into one category 
in the final model, rather than multiple imputation; 
multiple imputation makes the assumption that data 
are missing at random, which is often not the case with 
medical data.
The study had some weaknesses. Misclassification 
of coding for the exposures, outcomes, and covariates 
might exist, although previous evidence attests 
to the accuracy of CPRD16 and NHIRD data.17 23 24 
Assessments were made on the basis of prescriptions, 
and adherence to drugs was not monitored. We 
calculated the duration of disease before the index date 
from the first record of BPH; however, in some patients 
this coincided with the start of treatment (defined as 
duration of zero), and it is possible the disease was 
present before this time point. A dose-response relation 
could not be assessed because 5α-reductase inhibitors 
are only used at a single dose. We censored patients 
if they switched between dutasteride and finasteride 
but not if they stopped treatment; however, this 
would only underestimate the risk. The present study 
is observational, non-randomised, and unblinded, 
therefore we could not control for unmeasured 
confounding factors and biases using propensity score 
matching. General practice prescribing preferences 
were not available; this information could be used in 
Table 3 | Baseline characteristics for Taiwanese National Health Insurance Research Database cohorts receiving single drugs before and after 
propensity matching. Values are means (standard deviations) unless stated otherwise
Characteristics
Before propensity score matching After propensity score matching
Dutasteride 
(n=1251)
Finasteride 
(n=4194)
Tamsulosin 
(n=86 263) P value
Dutasteride 
(n=1251)
Finasteride 
(n=2445)
Tamsulosin 
(n=2502) P value
Age (years) 68.5 (10.1) 68.3 (10.5) 65.7 (11.6) <0.01 68.5 (10.1) 68.4 (10.7) 68.3 (10.4) 0.07
Body mass index category*: 
 <18.5 NA NA NA NA NA NA NA NA
 18.5-25 NA NA NA NA NA NA NA NA
 25-30 NA NA NA NA NA NA NA NA
 >30 NA NA NA NA NA NA NA NA
Smoking status*:                
 Yes NA NA NA NA NA NA NA NA
 No NA NA NA NA NA NA NA NA
 Former NA NA NA NA NA NA NA NA
Physical activity*:                
 Inactive NA NA NA NA NA NA NA NA
 Gentle NA NA NA NA NA NA NA NA
 Moderate NA NA NA NA NA NA NA NA
 Vigorous NA NA NA NA NA NA NA NA
Alcohol consumption*:                
 Yes NA NA NA NA NA NA NA NA
 No NA NA NA NA NA NA NA NA
 Former NA NA NA NA NA NA NA NA
Median (interquartile range) duration of BPH (days)* 30 (0-250) 28 (0-212) 21 (39-724) <0.01 30 (0-250) 28 (0-161) 44 (0-372) <0.01
Disease history (No (%))                
 COPD 106 (8.5) 415 (9.9) 7491 (8.7) <0.01 106 (8.5) 210 (8.6) 210 (8.4) 0.66
 Dyslipidaemia 284 (22.7) 630 (15) 14 609 (16.9) <0.01 284 (22.7) 545 (22.3) 588 (23.5) 0.61
 Hypertension 631 (50.4) 1829 (43.6) 36 653 (42.5) <0.01 631 (50.4) 1269 (51.9) 1231 (49.2) 0.11
Other drug use (No (%))†:
 β blocker 328 (26.2) 1024 (24.4) 20 868 (24.2) <0.01 328 (26.2) 645 (26.4) 668 (26.7) 0.71
 Statin 226 (18.1) 407 (9.7) 968 (11.2) <0.01 226 (18.1) 369 (15.1) 503 (20.1) 0.09
 ACE inhibitor 300 (24.0) 956 (22.8) 17 252 (20.0) <0.01 300 (24.0) 619 (25.3) 535 (21.4) 0.12
 ARB 131 (10.5) 481 (11.5) 8799 (10.2) <0.01 131 (10.5) 276 (11.3) 270 (10.8) 0.64
 Diuretic 168 (13.5) 620 (14.8) 12 718 (14.7) <0.01 168 (13.5) 296 (12.1) 353 (14.1) 0.43
 Oral corticosteroid 342 (27.3) 1095 (26.1) 24 177 (28.0) <0.01 342 (27.3) 719 (29.4) 681 (27.2) 0.14
No of outpatient visits‡ 11.6 (8.8) 9.9 (9.6) 10.3 (9.2) <0.01 11.6 (8.8) 10.2 (10.2) 11.2 (10.4) <0.01
ACE=angiotensin converting enzyme; ARB=angiotensin receptor blocker; BMI=body mass index; BPH=benign prostatic hyperplasia; COPD=chronic obstructive pulmonary disease; NA=not 
available.
*Excluding missing data.
†In previous year.
‡Three months before or three months after index date.
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an instrumental variable analysis, a technique that 
deals with unmeasured confounders. However, we 
anticipated that the impact of unmeasured cofounders 
would be small, in line with our previous findings for 
the Medicines Monitoring Unit database.25
The power in the CPRD study was constrained 
by the number of patients receiving dutasteride. 
Finasteride has been “off patent” for longer, whereas 
generic dutasteride has only been available since 
2014. However, given the substantial overlap in 
the risks between finasteride and dutasteride, and 
replication of the findings in Taiwan, a difference in 
risk would probably not be uncovered with larger 
numbers. The characteristics of the most appropriate 
control population in the setting of type 2 diabetes 
in BPH are debatable, and untreated patients are not 
available for study across a suitable timescale. There 
are inherent differences in disease severity in patients 
receiving tamsulosin compared with those receiving 
5α-reductase inhibitors; 5α-reductase inhibitors 
are prescribed in patients with enlarged prostates 
and tamsulosin is favoured as first line treatment for 
lower urinary tract symptoms. These differences in 
indications could differentiate between two patient 
populations that have varying susceptibilities to 
metabolic disease.
The most probable confounders are metabolic risk 
factors, and we sought to address these factors as 
far as possible through propensity score matching. 
Scoring with body mass index in the CPRD data 
allowed matching of obesity at the index date, and this 
did not change the outcome. However, longer duration 
of obesity before the study period might have resulted 
in an enlarged prostate and thus a greater likelihood 
of prescription of 5α-reductase inhibitors. We further 
analysed data with a time dependent variable of body 
mass index, and the results showed little difference. 
The propensity score matched analysis included only 
a quarter of the patient cohort because of predictable 
difficulties matching baseline variables in these 
cohorts with high precision. Although the possibilities 
of an unknown mechanism and reverse causality 
remain, the patient groups on 5α-reductase inhibitors 
are at an increased risk of type 2 diabetes.
An alternative hypothesis could be that tamsulosin 
might protect patients from developing type 2 diabetes 
as opposed to 5α-reductase inhibitors accelerating the 
process. However, because the diagnosis of BPH was 
made on presentation of symptoms and owing to the 
effectiveness of treatment, it was not possible to study 
patients without intervention over this timescale. 
Reassuringly, the rates of type 2 diabetes in patients 
receiving tamsulosin (approximately 60 per 10 000 
person years) were comparable to those in the general 
population (42-64 per 10 000 patients26). Importantly, 
inclusion of patients receiving tamsulosin combined 
with a 5α-reductase inhibitor revealed the same 
increased risks of type 2 diabetes as patients receiving 
a 5α-reductase inhibitor alone. However, numbers 
of patients using combination treatments were low, 
preventing a meaningful analysis of these groups.
In an additional analysis, we compared the rates of 
new incident type 2 diabetes with patients receiving 
surgical treatment: transurethral resection of the 
prostate. We found some evidence in the NHIRD cohort 
that patients receiving tamsulosin were less likely 
to develop type 2 diabetes than patients undergoing 
surgery, but this was not evident in the CPRD cohort 
(supplementary tables S5 and S6). However, these 
patient groups were poorly matched, even after 
propensity scoring. We conclude that there is a 
possibility tamsulosin offers some protection against 
type 2 diabetes, but there is an adverse effect of 
5α-reductase inhibitors. A randomised controlled trial 
is needed to study this hypothesis further.
Strengths and weaknesses in relation to other 
studies
In phase III trials of dutasteride, no evidence was found 
of increased blood glucose levels,27 28 but these studies 
were only for two years and were limited in statistical 
power. In this study, we observed the increased risk 
with 5α-reductase inhibitors after approximately 
three years of treatment, which is consistent with 
a previous report of the slow progression to type 2 
diabetes with obesity and changes in fasting glucose.12 
The only previous longer term observational studies 
were focused on heart failure and had inconsistent 
results.29 30 A previous pharmacoepidemiological study 
conducted over five years suggested a lower risk of type 
2 diabetes, but had smaller numbers of patients, a less 
well characterised control group, and importantly, did 
not include adjustment for body mass index.15
Based on previous experimental medicine studies, we 
anticipated an increased risk of type 2 diabetes only in 
the dutasteride cohort; the greater risk of type 2 diabetes 
in patients receiving finasteride contrasts with its lack of 
measurable effect on metabolism after three months of 
treatment.8 However, although the point measures of the 
hazard ratios suggest an increased risk of approximately 
30% in the UK population for dutasteride and 
finasteride, the relation was weaker with finasteride.
In rodents, disruption of 5αR1 but not 5αR2 causes 
insulin resistance, fatty liver, and susceptibility to 
liver fibrosis.13 14 However, in rodent liver only 5αR1 
is expressed, whereas in human liver both isozymes 
of 5α-reductases are present.8 Urinary steroid 
profiling in humans showed robust reductions in 
5α reduced steroid metabolites with finasteride and 
dutasteride,8 although dutasteride lowers circulating 
dihydrotestosterone to a greater extent than finasteride 
(approximately 90% v 70%).31 Thus, it is plausible that 
both drugs affect liver metabolism. However, changes 
in insulin sensitivity with dutasteride can be detected 
sooner using sensitive euglycemic hyperinsulinemic 
clamps because of its greater potency, while the 
more modest biochemical effect of finasteride has an 
accumulated risk over time.
Meaning of the study
Tamsulosin is recommended as first line treatment 
for patients with symptomatic BPH.10 5α-reductase 
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inhibitors are recommended especially in patients 
with larger prostates, but currently no guidance is 
available about choosing dutasteride or finasteride. In 
this study, the risk of type 2 diabetes was similar for 
dutasteride and finasteride. Patients receiving these 
drugs are older and more susceptible to metabolic 
disease. Therefore, it will be important to consider the 
risk of development or exacerbation of type 2 diabetes 
when prescribing these drugs and to apply suitable 
monitoring strategies.
This study should alert clinicians that patients 
starting 5α-reductase inhibitor treatment might 
benefit from early lifestyle advice and monitoring of 
type 2 diabetes.
Unanswered questions and future research
Why are patients receiving 5α-reductase inhibitors 
at increased risk of type 2 diabetes? 5α-reductases 
are highly expressed in the liver, but also in other 
tissues critical for insulin sensitivity—for example 
adipose tissue and skeletal muscle. The enzymes 
metabolise a range of steroids, including testosterone, 
cortisol, progesterone, and aldosterone. The increased 
susceptibility to type 2 diabetes might reflect changes 
in these hormones, most plausibly androgens or 
glucocorticoids. 5α-dihydrotestosterone is a more 
active androgen than testosterone, so inhibiting its 
formation with dutasteride or finasteride32 could 
induce features of androgen deficiency, which 
include insulin resistance. Low circulating levels of 
testosterone are associated with an increased risk 
of type 2 diabetes33 in men, a relation also obvious 
after androgen deprivation therapy in prostate 
cancer.34 Interestingly the patients we studied will 
have low 5α-dihydrotestosterone but their levels 
of testosterone are possibly higher; therefore, they 
would only be androgen deficient at a localised tissue 
level where 5α-reductases are expressed, including 
liver and adipose.8 Importantly castration in rodent 
models did not protect against the adverse metabolic 
effects of 5α-reductase inhibitors,13 which suggests 
other factors are at play. Prevention of inactivation of 
cortisol by 5α-reductases could lead to accumulation 
of glucocorticoid in metabolic tissues, again promoting 
insulin resistance.
The increased risk of type 2 diabetes has been studied 
up to 11 years and might continue to rise; therefore, 
patients would require longer follow-up, particularly 
considering treatment could be lifelong. Further 
investigation is now required to uncover whether these 
patients are also more at risk of diabetic complications. 
Finally, further studies could explore the unmeasured 
confounders by conducting an instrumental variable 
analysis, with the instrumental variable carefully 
chosen and validated.
Conclusion
Men using steroid 5α-reductase inhibitors for BPH 
appear to be at a modest increased risk of developing type 
2 diabetes. Caveats exist about biases and confounders 
within population cohort studies. However, in the light 
of our findings, the decision to prescribe 5α-reductase 
inhibitors for men with metabolic disease must be 
considered carefully in the context of other risk factors 
for type 2 diabetes. In addition, monitoring of fasting 
glucose might be advisable.
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